A joint venture formed by Apollo Global Management and RWE has acquired Amprion, a global leader in precision medicine for neurodegenerative disorders, for an undisclosed amount. This transaction involves the outright purchase of Amprion by the joint venture, marking a significant corporate acquisition in the diagnostics sector. Amprion specializes in advancing diagnostics for complex neurological conditions through its proprietary seed amplification testing technology.
Amprion's flagship product is the SAAmplify™-ɑSYN Biomarker Test, a first-in-class, qualitative Laboratory Developed Test (LDT). This test stands as the only seed amplification assay clinically available to aid the diagnosis of synucleinopathies, including Parkinson’s disease, Lewy body dementia, and Alzheimer’s disease with Lewy body variant. The SAAmplify™-ɑSYN test offers biological clarity by detecting pathological α-synuclein with autopsy-confirmed accuracy, supported by extensive scientific validation, including hundreds of autopsy confirmations and thousands of scientific publications and samples analyzed. Its utility has also received an FDA letter of support as a drug development tool.
The acquisition is strategically driven by the joint venture's interest in Amprion's innovative diagnostic platform and its established leadership in the burgeoning field of precision neurodegenerative medicine. This corporate buyout aims to accelerate the development and broader adoption of Amprion's critical diagnostic tools. Expected synergies include leveraging the joint venture's substantial resources to support Amprion's operational scale, research and development efforts, and market expansion. The integration is anticipated to further solidify Amprion's position as a pivotal player in early and accurate diagnosis of challenging neurological disorders, moving beyond traditional symptom-based assessments.
The combined entity is poised to enhance the availability and impact of advanced diagnostics for neurodegenerative diseases. This strategic move is expected to support Amprion's mission to provide biological certainty for patients, clinicians, and biopharma partners, ultimately aiming to improve treatment pathways and outcomes for millions affected by these conditions globally. The acquisition represents a long-term commitment to fostering innovation in a vital area of healthcare.